Regeneron Pharmaceuticals, Inc. (REGN) Sets New 52-Week High on Analyst Upgrade

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) hit a new 52-week high during mid-day trading on Tuesday after Piper Jaffray Companies raised their price target on the stock from $446.00 to $557.00. Piper Jaffray Companies currently has an overweight rating on the stock. Regeneron Pharmaceuticals traded as high as $500.00 and last traded at $500.00, with a volume of 3,062,551 shares traded. The stock had previously closed at $471.67.

REGN has been the subject of a number of other reports. Oppenheimer Holdings, Inc. started coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, March 16th. They issued a “hold” rating for the company. Vetr cut shares of Regeneron Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $368.84 price objective for the company. in a report on Monday, May 15th. Leerink Swann set a $448.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, March 28th. BTIG Research reiterated a “buy” rating and issued a $460.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, March 29th. Finally, Robert W. Baird reiterated a “neutral” rating and issued a $369.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, March 28th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and twelve have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $438.99.

In related news, Director Michael S. Brown sold 1,000 shares of the stock in a transaction dated Wednesday, March 29th. The shares were sold at an average price of $400.00, for a total value of $400,000.00. Following the completion of the transaction, the director now owns 1,000 shares of the company’s stock, valued at $400,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Robert J. Terifay sold 21,147 shares of the stock in a transaction dated Friday, June 16th. The stock was sold at an average price of $468.19, for a total transaction of $9,900,813.93. Following the completion of the transaction, the executive vice president now directly owns 72,043 shares of the company’s stock, valued at approximately $33,729,812.17. The disclosure for this sale can be found here. Insiders sold 46,821 shares of company stock valued at $21,753,312 in the last three months. Company insiders own 10.40% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Concert Wealth Management Inc. raised its position in Regeneron Pharmaceuticals by 0.4% in the first quarter. Concert Wealth Management Inc. now owns 723 shares of the biopharmaceutical company’s stock valued at $269,000 after buying an additional 3 shares during the period. Cleararc Capital Inc. raised its stake in Regeneron Pharmaceuticals by 0.3% in the first quarter. Cleararc Capital Inc. now owns 1,850 shares of the biopharmaceutical company’s stock valued at $717,000 after buying an additional 5 shares during the last quarter. Sheaff Brock Investment Advisors LLC raised its stake in Regeneron Pharmaceuticals by 1.4% in the first quarter. Sheaff Brock Investment Advisors LLC now owns 750 shares of the biopharmaceutical company’s stock valued at $291,000 after buying an additional 10 shares during the last quarter. Alpha Windward LLC raised its stake in Regeneron Pharmaceuticals by 4.4% in the first quarter. Alpha Windward LLC now owns 383 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 16 shares during the last quarter. Finally, Grandfield & Dodd LLC raised its stake in Regeneron Pharmaceuticals by 1.1% in the first quarter. Grandfield & Dodd LLC now owns 1,497 shares of the biopharmaceutical company’s stock valued at $580,000 after buying an additional 17 shares during the last quarter. 67.23% of the stock is owned by hedge funds and other institutional investors.

The firm has a 50 day moving average of $453.36 and a 200-day moving average of $392.99. The stock has a market capitalization of $52.78 billion, a P/E ratio of 60.52 and a beta of 1.53.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, May 4th. The biopharmaceutical company reported $2.92 EPS for the quarter, beating the consensus estimate of $2.50 by $0.42. The company had revenue of $1.32 billion during the quarter, compared to analysts’ expectations of $1.30 billion. Regeneron Pharmaceuticals had a net margin of 19.34% and a return on equity of 22.99%. The business’s revenue for the quarter was up 9.8% compared to the same quarter last year. During the same period in the previous year, the company earned $2.57 EPS. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post $12.66 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Regeneron Pharmaceuticals, Inc. (REGN) Sets New 52-Week High on Analyst Upgrade” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/2655915/regeneron-pharmaceuticals-inc-regn-sets-new-52-week-high-on-analyst-upgrade.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:REGN”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.